Lymph node-targeted Nanovaccine Reshapes the Tumor Microenvironment to Suppress PDAC Progression and Metastasis

Abstract excerpt

<title>Abstract</title> <p>Pancreatic ductal adenocarcinoma (PDAC) is lethal in ~88% of patients. Immunotherapy has revolutionized cancer therapy for many cancer types; however, PDAC survival rates remain unchanged. Low tumor mutation burden, inefficient antigen presentation, limited response rates to standard-of-care (SoC) therapy, acquired resistance, and a profoundly immunosuppressive microenvironment constrai...

Topics

Open a Topic to create a Post that cites this publication.

• Carcinoma, Pancreatic Ductal
• Combined Modality Therapy
• Immunotherapy
• Mutation
• Oncogene Protein p21(ras)
• Pancreatic Neoplasms
• Proto-Oncogene Proteins p21(ras)
• Tumor Microenvironment

Identifiers and source

Literature Corpus work

7fd59ded-bb8c-5741-959f-feb52af0671f

DOI

10.21203/rs.3.rs-9958073/v1